Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Aug 1;95(5):1399-1404.
doi: 10.1016/j.ijrobp.2016.03.050. Epub 2016 Apr 8.

Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy

Kamran A Ahmed  1 , Jimmy J Caudell  1 , Ghassan El-Haddad  2 , Anders E Berglund  3 , Eric A Welsh  3 , Binglin Yue  4 , Sarah E Hoffe  1 , Arash O Naghavi  1 , Yazan A Abuodeh  1 , Jessica M Frakes  1 , Steven A Eschrich  3 , Javier F Torres-Roca  5
Affiliations
Observational Study

Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy

Kamran A Ahmed et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose/objectives: Evidence from the management of oligometastases with stereotactic body radiation therapy (SBRT) reveals differences in outcomes based on primary histology. We have previously identified a multigene expression index for tumor radiosensitivity (RSI) with validation in multiple independent cohorts. In this study, we assessed RSI in liver metastases and assessed our clinical outcomes after SBRT based on primary histology.

Methods and materials: Patients were identified from our prospective, observational protocol. The previously tested RSI 10 gene assay was run on samples and calculated using the published algorithm. An independent cohort of 33 patients with 38 liver metastases treated with SBRT was used for clinical correlation.

Results: A total of 372 unique metastatic liver lesions were identified for inclusion from our prospective, institutional metadata pool. The most common primary histologies for liver metastases were colorectal adenocarcinoma (n=314, 84.4%), breast adenocarcinoma (n=12, 3.2%), and pancreas neuroendocrine (n=11, 3%). There were significant differences in RSI of liver metastases based on histology. The median RSIs for liver metastases in descending order of radioresistance were gastrointestinal stromal tumor (0.57), melanoma (0.53), colorectal neuroendocrine (0.46), pancreas neuroendocrine (0.44), colorectal adenocarcinoma (0.43), breast adenocarcinoma (0.35), lung adenocarcinoma (0.31), pancreas adenocarcinoma (0.27), anal squamous cell cancer (0.22), and small intestine neuroendocrine (0.21) (P<.0001). The 12-month and 24-month Kaplan-Meier rates of local control (LC) for colorectal lesions from the independent clinical cohort were 79% and 59%, compared with 100% for noncolorectal lesions (P=.019), respectively.

Conclusions: In this analysis, we found significant differences based on primary histology. This study suggests that primary histology may be an important factor to consider in SBRT radiation dose selection.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Steven A. Eschrich and Javier F. Torres-Roca report stock and leadership in Cvergenx, Inc and royalty and patents on RSI. The authors report no other conflict of interest.

Figures

Fig. 1.
Fig. 1.
Box plot of radiosensitive index (RSI) values of liver metastases based on primary histology. Abbreviation: GIST = gastrointestinal stromal tumor. Unfilled diamonds represent outliers using the standard 1.5 interquartile range rule.
Fig. 2.
Fig. 2.
Kaplan-Meier local control rates for colorectal and noncolorectal liver metastases.
See this image and copyright information in PMC

Comment in

References

    1. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial. J Clin Oncol 2001; 19:164–170. - PubMed
    1. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006; 45:823–830. - PubMed
    1. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009; 27:1585–1591. - PubMed
    1. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radial Oncol Biol Phys 2013;86:336–342. - PubMed
    1. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572–1578. - PubMed

Publication types

MeSH terms